

## Disclosures

### Personal Commercial (20)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Vascular Medicine Prevention</i>
AstraZeneca Pharmaceuticals	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Other</i>
Athera biotechnologies	Other - <i>Scientific Advisory Board</i>	None (\$0)	<i>Vascular Medicine</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Acute Coronary Syndromes</i>
Bristol-Myers Squibb Company	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Vascular Medicine</i>
DalCor Pharmaceuticals	Other - <i>Scientific Advisory Board</i>	None (\$0)	
Eli Lilly and Company	Other - <i>Unpaid consultant</i>	None (\$0)	
Esperion Therapeutics	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Vascular Medicine</i>
General Electric	Research/Research Grants	Modest (< \$5,000)	<i>Noninvasive Imaging Other</i>
Genzyme Corporation	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Acute Coronary Syndromes</i>
GlaxoSmithKline	Research/Research Grants	Modest (< \$5,000)	<i>Prevention Vascular Medicine</i>
Interleukin Genetics	Other - <i>Scientific Advisory Board</i>	Significant (>= \$5,000)	<i>Vascular Medicine</i>
Ionis Pharmaceuticals	Other - <i>Unpaid consultant</i>	None (\$0)	
Kowa Pharmaceuticals	Other - <i>Scientific Advisory Board</i>	None (\$0)	
Merck & Co., Inc.	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Acute Coronary Syndromes</i>
Novartis	Other - <i>Unpaid consultant</i>	None (\$0)	<i>General Cardiology Prevention Vascular Medicine</i>
Novartis	Research/Research Grants	Modest (< \$5,000)	<i>Vascular Medicine</i>
Pfizer	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Vascular Medicine Prevention</i>
Sanofi-Regeneron	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Acute Coronary Syndromes</i>
Takeda Pharmaceuticals North America, Inc	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Vascular Medicine</i>

### Personal Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (1)

Funding Source

Institutional Compensation Level

## Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

---

Certified Education Attestation | Signed on 8/24/2015

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/24/2015

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

Embargo | Signed on 8/24/2015

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

On-Going Obligation Agreement | Signed on 3/31/2016

### ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.